161 related articles for article (PubMed ID: 36821433)
1. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
[TBL] [Abstract][Full Text] [Related]
2. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
4. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
6. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
7. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
8. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.
Kim S; Bang JI; Boo D; Kim B; Choi IY; Ko S; Yoo IR; Kim K; Kim J; Joo Y; Ryoo HG; Paeng JC; Park JM; Jang W; Kim B; Chung Y; Yang D; Yoo S; Lee HY
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3547-3556. PubMed ID: 35362796
[TBL] [Abstract][Full Text] [Related]
9. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.
Wu W; Li S; Xu K; Meng Z
Endokrynol Pol; 2023; 74(3):260-270. PubMed ID: 37335064
[TBL] [Abstract][Full Text] [Related]
10. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
[TBL] [Abstract][Full Text] [Related]
11. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
12. Cancer Risk in Graves Disease with Radioactive
Kim KJ; Choi J; Kim KJ; Song E; Yu JH; Kim NH; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG
J Nucl Med; 2024 May; 65(5):693-699. PubMed ID: 38548348
[TBL] [Abstract][Full Text] [Related]
13. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
[TBL] [Abstract][Full Text] [Related]
14. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M
Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230
[TBL] [Abstract][Full Text] [Related]
15. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study.
Kim M; Kim H; Park S; Joo J; Kim IJ; Kim BH
Eur J Endocrinol; 2022 Apr; 186(5):561-571. PubMed ID: 35286279
[TBL] [Abstract][Full Text] [Related]
17. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.
Lee JY; Woo KI
Thyroid; 2022 May; 32(5):544-551. PubMed ID: 34894720
[No Abstract] [Full Text] [Related]
18. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
[TBL] [Abstract][Full Text] [Related]
20. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
Seo GH; Kong KA; Kim BS; Kang SY; Moon BS; Yoon HJ; Kim HO
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2580-e2588. PubMed ID: 33755732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]